James J Farrell MD

Associate Professor of Medicine (Digestive Diseases); Director, Yale Center for Pancreatic Diseases

Departments & Organizations

Office of Student ResearchCancer Center, Yale: Gastrointestinal Cancer Program; Thoracic Oncology Program; Developmental TherapeuticsInternal Medicine: Digestive Diseases: Interventional Endoscopy Program

Research Interests

Pancreatic Cancer Early Diagnosis; Pancreatic Cystic Neoplasms, Pancreatic Biomarkers, Personalized Medicine, Pancreatic Disease, Gastrointestinal Oncoloy more...


  • M.B.Ch.B., University College, Dublin, Ireland, 1992

Selected Publications

  • Farrell JJ, Elsaleh H, Garcia M, Lai R, Ammar A, Regine W, Abrams R, Bowen Benson A, Macdonald J, Cass CA, Mackey JA..Human ENT1 is predictive of response to gemcitabine treatment in patients with pancreatic cancer: Results from the RTOG 9704 Prospective Randomized Trial. Gastroenterology 2009 Jan;136(1):187-95
  • Weinberg B, Spiegel B, Tomlinson J, Farrell JJ. Asymptomatic Pancreatic Cysts: Maximizing Survival and Quality of Life using Markov-based Clinical Nomograms Gastroenterology 2010Feb;138(2):531-40
  • Farrell JJ Garcia M, Elshimali YI, Guha C, Dicker A, Elsaleh H Cytidine Deaminase Single Nucleotide Polymorphism is Predictive of Toxicity from Gemcitabine in Patients with Pancreatic Cancer. The Pharmacogenomics Journal 2011 May 31



Latest News


Edit Profile